NO323110B1 - Preparat innbefattende en nukleinsyre og kationisk polymer samt anvendelse av polymeren. - Google Patents
Preparat innbefattende en nukleinsyre og kationisk polymer samt anvendelse av polymeren. Download PDFInfo
- Publication number
- NO323110B1 NO323110B1 NO19970049A NO970049A NO323110B1 NO 323110 B1 NO323110 B1 NO 323110B1 NO 19970049 A NO19970049 A NO 19970049A NO 970049 A NO970049 A NO 970049A NO 323110 B1 NO323110 B1 NO 323110B1
- Authority
- NO
- Norway
- Prior art keywords
- preparation according
- nucleic acid
- polymer
- cells
- transfection
- Prior art date
Links
- 108020004707 nucleic acids Proteins 0.000 title claims abstract description 65
- 102000039446 nucleic acids Human genes 0.000 title claims abstract description 65
- 150000007523 nucleic acids Chemical class 0.000 title claims abstract description 59
- 229920006317 cationic polymer Polymers 0.000 title claims abstract description 19
- 238000002360 preparation method Methods 0.000 title claims description 66
- 229920000642 polymer Polymers 0.000 title claims description 25
- 238000012546 transfer Methods 0.000 claims abstract description 38
- 108090000623 proteins and genes Proteins 0.000 claims description 63
- 238000001890 transfection Methods 0.000 claims description 47
- 229920002873 Polyethylenimine Polymers 0.000 claims description 30
- 108020004414 DNA Proteins 0.000 claims description 24
- 229910019142 PO4 Inorganic materials 0.000 claims description 22
- 150000002632 lipids Chemical class 0.000 claims description 22
- 102000004169 proteins and genes Human genes 0.000 claims description 21
- 235000021317 phosphate Nutrition 0.000 claims description 18
- 230000001225 therapeutic effect Effects 0.000 claims description 16
- 150000001412 amines Chemical class 0.000 claims description 15
- OPCHFPHZPIURNA-MFERNQICSA-N (2s)-2,5-bis(3-aminopropylamino)-n-[2-(dioctadecylamino)acetyl]pentanamide Chemical compound CCCCCCCCCCCCCCCCCCN(CC(=O)NC(=O)[C@H](CCCNCCCN)NCCCN)CCCCCCCCCCCCCCCCCC OPCHFPHZPIURNA-MFERNQICSA-N 0.000 claims description 11
- 230000001413 cellular effect Effects 0.000 claims description 11
- -1 nucleic acid phosphate Chemical class 0.000 claims description 11
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 11
- 239000010452 phosphate Substances 0.000 claims description 10
- 230000007935 neutral effect Effects 0.000 claims description 9
- MWRBNPKJOOWZPW-CLFAGFIQSA-N dioleoyl phosphatidylethanolamine Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(COP(O)(=O)OCCN)OC(=O)CCCCCCC\C=C/CCCCCCCC MWRBNPKJOOWZPW-CLFAGFIQSA-N 0.000 claims description 8
- 150000003013 phosphoric acid derivatives Chemical class 0.000 claims description 8
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 7
- 239000012634 fragment Substances 0.000 claims description 6
- 239000000203 mixture Substances 0.000 claims description 6
- 102000053602 DNA Human genes 0.000 claims description 4
- 229920000333 poly(propyleneimine) Polymers 0.000 claims description 4
- 235000000346 sugar Nutrition 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 3
- 229910052739 hydrogen Inorganic materials 0.000 claims description 3
- 239000001257 hydrogen Substances 0.000 claims description 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 3
- 239000003446 ligand Substances 0.000 claims description 3
- LRYZPFWEZHSTHD-HEFFAWAOSA-O 2-[[(e,2s,3r)-2-formamido-3-hydroxyoctadec-4-enoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium Chemical class CCCCCCCCCCCCC\C=C\[C@@H](O)[C@@H](NC=O)COP(O)(=O)OCC[N+](C)(C)C LRYZPFWEZHSTHD-HEFFAWAOSA-O 0.000 claims description 2
- ZXWQZGROTQMXME-WXUJBLQXSA-N 2-hydroxy-n-[(e,2s,3r)-3-hydroxy-1-[(2r,3r,4s,5r,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoctadec-4-en-2-yl]tetracosanamide Chemical class CCCCCCCCCCCCCCCCCCCCCCC(O)C(=O)N[C@H]([C@H](O)\C=C\CCCCCCCCCCCCC)CO[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O ZXWQZGROTQMXME-WXUJBLQXSA-N 0.000 claims description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 2
- 229930183167 cerebroside Natural products 0.000 claims description 2
- 150000001784 cerebrosides Chemical class 0.000 claims description 2
- 150000001982 diacylglycerols Chemical class 0.000 claims description 2
- 210000004400 mucous membrane Anatomy 0.000 claims description 2
- 230000004962 physiological condition Effects 0.000 claims description 2
- 229920002477 rna polymer Polymers 0.000 claims description 2
- 150000003408 sphingolipids Chemical class 0.000 claims description 2
- 229920001059 synthetic polymer Polymers 0.000 claims description 2
- 239000007972 injectable composition Substances 0.000 claims 1
- 238000001727 in vivo Methods 0.000 abstract description 13
- 238000001415 gene therapy Methods 0.000 abstract description 3
- 210000004027 cell Anatomy 0.000 description 64
- 239000013612 plasmid Substances 0.000 description 42
- 239000000243 solution Substances 0.000 description 25
- 210000002950 fibroblast Anatomy 0.000 description 18
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 14
- 239000000047 product Substances 0.000 description 13
- 230000000694 effects Effects 0.000 description 12
- 238000000034 method Methods 0.000 description 11
- 108060001084 Luciferase Proteins 0.000 description 10
- 239000005089 Luciferase Substances 0.000 description 10
- 108091034117 Oligonucleotide Proteins 0.000 description 10
- 210000002569 neuron Anatomy 0.000 description 9
- 108020003175 receptors Proteins 0.000 description 9
- 102000005962 receptors Human genes 0.000 description 9
- 239000013598 vector Substances 0.000 description 8
- 108010039918 Polylysine Proteins 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 7
- 229920000656 polylysine Polymers 0.000 description 7
- 210000002966 serum Anatomy 0.000 description 7
- 239000011780 sodium chloride Substances 0.000 description 7
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 6
- 241000700605 Viruses Species 0.000 description 6
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 239000006228 supernatant Substances 0.000 description 6
- 108010035563 Chloramphenicol O-acetyltransferase Proteins 0.000 description 5
- 108010076504 Protein Sorting Signals Proteins 0.000 description 5
- 210000004556 brain Anatomy 0.000 description 5
- 239000002609 medium Substances 0.000 description 5
- 210000000056 organ Anatomy 0.000 description 5
- 238000011144 upstream manufacturing Methods 0.000 description 5
- 241000701022 Cytomegalovirus Species 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- 125000002091 cationic group Chemical group 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 230000000890 antigenic effect Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 230000002068 genetic effect Effects 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 108020004999 messenger RNA Proteins 0.000 description 3
- 230000007170 pathology Effects 0.000 description 3
- 229920000768 polyamine Polymers 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- PFNFFQXMRSDOHW-UHFFFAOYSA-N spermine Chemical compound NCCCNCCCCNCCCN PFNFFQXMRSDOHW-UHFFFAOYSA-N 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 239000005495 thyroid hormone Substances 0.000 description 3
- 229940036555 thyroid hormone Drugs 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 238000011282 treatment Methods 0.000 description 3
- WHTVZRBIWZFKQO-AWEZNQCLSA-N (S)-chloroquine Chemical compound ClC1=CC=C2C(N[C@@H](C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-AWEZNQCLSA-N 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- ZKHQWZAMYRWXGA-KQYNXXCUSA-N Adenosine triphosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-N 0.000 description 2
- ZKHQWZAMYRWXGA-UHFFFAOYSA-N Adenosine triphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O ZKHQWZAMYRWXGA-UHFFFAOYSA-N 0.000 description 2
- RGJOEKWQDUBAIZ-IBOSZNHHSA-N CoASH Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCS)O[C@H]1N1C2=NC=NC(N)=C2N=C1 RGJOEKWQDUBAIZ-IBOSZNHHSA-N 0.000 description 2
- IGXWBGJHJZYPQS-SSDOTTSWSA-N D-Luciferin Chemical compound OC(=O)[C@H]1CSC(C=2SC3=CC=C(O)C=C3N=2)=N1 IGXWBGJHJZYPQS-SSDOTTSWSA-N 0.000 description 2
- CYCGRDQQIOGCKX-UHFFFAOYSA-N Dehydro-luciferin Natural products OC(=O)C1=CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 CYCGRDQQIOGCKX-UHFFFAOYSA-N 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 108090000368 Fibroblast growth factor 8 Proteins 0.000 description 2
- BJGNCJDXODQBOB-UHFFFAOYSA-N Fivefly Luciferin Natural products OC(=O)C1CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 BJGNCJDXODQBOB-UHFFFAOYSA-N 0.000 description 2
- DDWFXDSYGUXRAY-UHFFFAOYSA-N Luciferin Natural products CCc1c(C)c(CC2NC(=O)C(=C2C=C)C)[nH]c1Cc3[nH]c4C(=C5/NC(CC(=O)O)C(C)C5CC(=O)O)CC(=O)c4c3C DDWFXDSYGUXRAY-UHFFFAOYSA-N 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- AUYYCJSJGJYCDS-LBPRGKRZSA-N Thyrolar Chemical class IC1=CC(C[C@H](N)C(O)=O)=CC(I)=C1OC1=CC=C(O)C(I)=C1 AUYYCJSJGJYCDS-LBPRGKRZSA-N 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 229960003677 chloroquine Drugs 0.000 description 2
- WHTVZRBIWZFKQO-UHFFFAOYSA-N chloroquine Natural products ClC1=CC=C2C(NC(C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-UHFFFAOYSA-N 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- RGJOEKWQDUBAIZ-UHFFFAOYSA-N coenzime A Natural products OC1C(OP(O)(O)=O)C(COP(O)(=O)OP(O)(=O)OCC(C)(C)C(O)C(=O)NCCC(=O)NCCS)OC1N1C2=NC=NC(N)=C2N=C1 RGJOEKWQDUBAIZ-UHFFFAOYSA-N 0.000 description 2
- 239000005516 coenzyme A Substances 0.000 description 2
- 229940093530 coenzyme a Drugs 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 230000009089 cytolysis Effects 0.000 description 2
- 231100000263 cytotoxicity test Toxicity 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- KDTSHFARGAKYJN-UHFFFAOYSA-N dephosphocoenzyme A Natural products OC1C(O)C(COP(O)(=O)OP(O)(=O)OCC(C)(C)C(O)C(=O)NCCC(=O)NCCS)OC1N1C2=NC=NC(N)=C2N=C1 KDTSHFARGAKYJN-UHFFFAOYSA-N 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 150000004985 diamines Chemical class 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 210000003494 hepatocyte Anatomy 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000030648 nucleus localization Effects 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 102000005162 pleiotrophin Human genes 0.000 description 2
- 238000006068 polycondensation reaction Methods 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000010076 replication Effects 0.000 description 2
- 210000002460 smooth muscle Anatomy 0.000 description 2
- 150000008163 sugars Chemical class 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 206010046766 uterine cancer Diseases 0.000 description 2
- 208000012991 uterine carcinoma Diseases 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 239000002023 wood Substances 0.000 description 2
- 101150072531 10 gene Proteins 0.000 description 1
- 102100022464 5'-nucleotidase Human genes 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 102000007592 Apolipoproteins Human genes 0.000 description 1
- 108010071619 Apolipoproteins Proteins 0.000 description 1
- 102000013918 Apolipoproteins E Human genes 0.000 description 1
- 108010025628 Apolipoproteins E Proteins 0.000 description 1
- 102000005427 Asialoglycoprotein Receptor Human genes 0.000 description 1
- NOWKCMXCCJGMRR-UHFFFAOYSA-N Aziridine Chemical compound C1CN1 NOWKCMXCCJGMRR-UHFFFAOYSA-N 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 108090000715 Brain-derived neurotrophic factor Proteins 0.000 description 1
- 102000004219 Brain-derived neurotrophic factor Human genes 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 102000053642 Catalytic RNA Human genes 0.000 description 1
- 108090000994 Catalytic RNA Proteins 0.000 description 1
- 108010005939 Ciliary Neurotrophic Factor Proteins 0.000 description 1
- 102100031614 Ciliary neurotrophic factor Human genes 0.000 description 1
- 201000003883 Cystic fibrosis Diseases 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000000311 Cytosine Deaminase Human genes 0.000 description 1
- 108010080611 Cytosine Deaminase Proteins 0.000 description 1
- 230000033616 DNA repair Effects 0.000 description 1
- 241000702421 Dependoparvovirus Species 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 102000001039 Dystrophin Human genes 0.000 description 1
- 108010069091 Dystrophin Proteins 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 108090000386 Fibroblast Growth Factor 1 Proteins 0.000 description 1
- 102100031706 Fibroblast growth factor 1 Human genes 0.000 description 1
- 102100024785 Fibroblast growth factor 2 Human genes 0.000 description 1
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 1
- 102000004038 Glia Maturation Factor Human genes 0.000 description 1
- 108090000495 Glia Maturation Factor Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 241000700721 Hepatitis B virus Species 0.000 description 1
- 101000678236 Homo sapiens 5'-nucleotidase Proteins 0.000 description 1
- 101000599951 Homo sapiens Insulin-like growth factor I Proteins 0.000 description 1
- 101000611183 Homo sapiens Tumor necrosis factor Proteins 0.000 description 1
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 1
- 241000725303 Human immunodeficiency virus Species 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 1
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 102100037852 Insulin-like growth factor I Human genes 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- 108090001090 Lectins Proteins 0.000 description 1
- 102000004856 Lectins Human genes 0.000 description 1
- 102000008072 Lymphokines Human genes 0.000 description 1
- 108010074338 Lymphokines Proteins 0.000 description 1
- 101001055320 Myxine glutinosa Insulin-like growth factor Proteins 0.000 description 1
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 1
- 108090000742 Neurotrophin 3 Proteins 0.000 description 1
- 108010089610 Nuclear Proteins Proteins 0.000 description 1
- 102000007999 Nuclear Proteins Human genes 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 239000012979 RPMI medium Substances 0.000 description 1
- 108700005075 Regulator Genes Proteins 0.000 description 1
- 108700008625 Reporter Genes Proteins 0.000 description 1
- 108091027981 Response element Proteins 0.000 description 1
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 1
- 101100379247 Salmo trutta apoa1 gene Proteins 0.000 description 1
- 102100032889 Sortilin Human genes 0.000 description 1
- 102000019259 Succinate Dehydrogenase Human genes 0.000 description 1
- 108010012901 Succinate Dehydrogenase Proteins 0.000 description 1
- 241000701093 Suid alphaherpesvirus 1 Species 0.000 description 1
- 102000006601 Thymidine Kinase Human genes 0.000 description 1
- 108020004440 Thymidine kinase Proteins 0.000 description 1
- 102000044209 Tumor Suppressor Genes Human genes 0.000 description 1
- 108700025716 Tumor Suppressor Genes Proteins 0.000 description 1
- 102100040247 Tumor necrosis factor Human genes 0.000 description 1
- 101710108383 UDP-glucose:protein N-beta-glucosyltransferase Proteins 0.000 description 1
- 108700005077 Viral Genes Proteins 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 238000010539 anionic addition polymerization reaction Methods 0.000 description 1
- 108010006523 asialoglycoprotein receptor Proteins 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 239000003914 blood derivative Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 210000003855 cell nucleus Anatomy 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 230000009918 complex formation Effects 0.000 description 1
- 238000010668 complexation reaction Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 230000007515 enzymatic degradation Effects 0.000 description 1
- 230000009144 enzymatic modification Effects 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 239000011888 foil Substances 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 229920000140 heteropolymer Polymers 0.000 description 1
- 229920001519 homopolymer Polymers 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 150000002430 hydrocarbons Chemical group 0.000 description 1
- 150000002466 imines Chemical class 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 229940047124 interferons Drugs 0.000 description 1
- 229940047122 interleukins Drugs 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 150000002540 isothiocyanates Chemical class 0.000 description 1
- 239000000644 isotonic solution Substances 0.000 description 1
- 210000003292 kidney cell Anatomy 0.000 description 1
- 239000002523 lectin Substances 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- VMGAPWLDMVPYIA-HIDZBRGKSA-N n'-amino-n-iminomethanimidamide Chemical compound N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 230000000269 nucleophilic effect Effects 0.000 description 1
- 210000004940 nucleus Anatomy 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 230000007918 pathogenicity Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 229940021222 peritoneal dialysis isotonic solution Drugs 0.000 description 1
- 125000005342 perphosphate group Chemical group 0.000 description 1
- 239000013600 plasmid vector Substances 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 231100000683 possible toxicity Toxicity 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 108091092562 ribozyme Proteins 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 230000009962 secretion pathway Effects 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 229940063675 spermine Drugs 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 230000001228 trophic effect Effects 0.000 description 1
- 230000001173 tumoral effect Effects 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 210000001635 urinary tract Anatomy 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 239000013603 viral vector Substances 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biotechnology (AREA)
- Animal Behavior & Ethology (AREA)
- General Engineering & Computer Science (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biophysics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Virology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Saccharide Compounds (AREA)
- Polyamides (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Compositions Of Macromolecular Compounds (AREA)
- Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR9408735A FR2722506B1 (fr) | 1994-07-13 | 1994-07-13 | Composition contenant des acides nucleiques, preparation et utilisations |
| PCT/FR1995/000914 WO1996002655A1 (fr) | 1994-07-13 | 1995-07-07 | Composition contenant des acides nucleiques, preparation et utilisations |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| NO970049L NO970049L (no) | 1997-01-07 |
| NO970049D0 NO970049D0 (no) | 1997-01-07 |
| NO323110B1 true NO323110B1 (no) | 2007-01-02 |
Family
ID=9465376
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO19970049A NO323110B1 (no) | 1994-07-13 | 1997-01-07 | Preparat innbefattende en nukleinsyre og kationisk polymer samt anvendelse av polymeren. |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US6013240A (pt) |
| EP (1) | EP0770140B1 (pt) |
| JP (1) | JP4275728B2 (pt) |
| KR (1) | KR100424802B1 (pt) |
| AT (1) | ATE367448T1 (pt) |
| AU (1) | AU2930795A (pt) |
| CA (1) | CA2194797C (pt) |
| DE (1) | DE69535540T9 (pt) |
| DK (1) | DK0770140T3 (pt) |
| ES (1) | ES2290952T3 (pt) |
| FI (1) | FI119738B (pt) |
| FR (1) | FR2722506B1 (pt) |
| IL (1) | IL114566A (pt) |
| MX (1) | MX9700270A (pt) |
| NO (1) | NO323110B1 (pt) |
| PT (1) | PT770140E (pt) |
| WO (1) | WO1996002655A1 (pt) |
| ZA (1) | ZA955849B (pt) |
Families Citing this family (124)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2730637B1 (fr) | 1995-02-17 | 1997-03-28 | Rhone Poulenc Rorer Sa | Composition pharmaceutique contenant des acides nucleiques, et ses utilisations |
| IL122290A0 (en) * | 1995-06-07 | 1998-04-05 | Inex Pharmaceuticals Corp | Lipid-nucleic acid complex its preparation and use |
| US7422902B1 (en) | 1995-06-07 | 2008-09-09 | The University Of British Columbia | Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer |
| FR2739292B1 (fr) * | 1995-09-28 | 1997-10-31 | Rhone Poulenc Rorer Sa | Composition pharmaceutique utile pour la transfection d'acides nucleiques et ses utilisations |
| GB2324534B (en) * | 1996-01-06 | 2000-05-10 | Danbiosyst Uk | Composition for delivery of nucleic acid to a cell |
| EP0934082B1 (de) * | 1996-10-23 | 2002-07-17 | SKW Trostberg Aktiengesellschaft | Verfahren zur herstellung von biologisch aktiven polymernanopartikel-nucleinsäure-konjugaten |
| CA2271325A1 (en) * | 1996-11-12 | 1998-05-22 | The Regents Of The University Of California | Preparation of stable formulations of lipid-nucleic acid complexes for efficient in vivo delivery |
| US6884430B1 (en) * | 1997-02-10 | 2005-04-26 | Aventis Pharma S.A. | Formulation of stabilized cationic transfection agent(s) /nucleic acid particles |
| ATE466948T1 (de) * | 1997-03-11 | 2010-05-15 | Univ Minnesota | Dns-basiertes transposon-system für die einführung von nucleinsäure in die dns einer zelle |
| US5912225A (en) | 1997-04-14 | 1999-06-15 | Johns Hopkins Univ. School Of Medicine | Biodegradable poly (phosphoester-co-desaminotyrosyl L-tyrosine ester) compounds, compositions, articles and methods for making and using the same |
| US6524613B1 (en) | 1997-04-30 | 2003-02-25 | Regents Of The University Of Minnesota | Hepatocellular chimeraplasty |
| DE19726186A1 (de) * | 1997-06-20 | 1998-12-24 | Boehringer Ingelheim Int | Komplexe für den Transport von Nukleinsäure in höhere eukaryotische Zellen |
| EA003832B1 (ru) | 1997-09-15 | 2003-10-30 | Дженетик Иммьюнити, Ллс. | Ген-доставочный комплекс для чрескожной доставки чужеродного генетического материала в антиген-презентирующие клетки и способы его использования |
| US20020022034A1 (en) * | 1997-09-15 | 2002-02-21 | Julianna Lisziewicz | Therapeutic DNA vaccination |
| DE19743135A1 (de) | 1997-09-30 | 1999-04-01 | Hoechst Marion Roussel De Gmbh | Biologisch verträgliche niedermolekular Polyethylenimine |
| AU4697099A (en) * | 1998-06-18 | 2000-01-05 | Johns Hopkins University School Of Medicine, The | Polymers for delivery of nucleic acids |
| US6916490B1 (en) | 1998-07-23 | 2005-07-12 | UAB Research Center | Controlled release of bioactive substances |
| WO2000025748A1 (fr) * | 1998-11-02 | 2000-05-11 | Terumo Kabushiki Kaisha | Liposomes |
| US7160682B2 (en) * | 1998-11-13 | 2007-01-09 | Regents Of The University Of Minnesota | Nucleic acid transfer vector for the introduction of nucleic acid into the DNA of a cell |
| WO2000059548A1 (en) * | 1999-04-02 | 2000-10-12 | Research Development Foundation | Polyethyleneimine:dna formulations for aerosol delivery |
| US6770740B1 (en) | 1999-07-13 | 2004-08-03 | The Regents Of The University Of Michigan | Crosslinked DNA condensate compositions and gene delivery methods |
| FR2797402B1 (fr) | 1999-07-15 | 2004-03-12 | Biomerieux Stelhys | Utilisation d'un polypeptide pour detecter, prevenir ou traiter un etat pathologique associe a une maladie degenerative, neurologique ou autoimmune |
| DE19960206A1 (de) * | 1999-12-14 | 2001-07-19 | Frank Czubayko | Komplexierung von RNS mit Polyethyleniminen zur deren Stabilisierung und zellulären Einschleusung |
| AU782912B2 (en) | 1999-12-28 | 2005-09-08 | Association Francaise Contre Les Myopathies | Use of lithium (Li+) for the preparation of a composition for transfection of a polynucleotide into a cell and compositions useful in gene therapy |
| EP1242609A2 (en) * | 1999-12-30 | 2002-09-25 | Novartis AG | Novel colloid synthetic vectors for gene therapy |
| FR2805271B1 (fr) * | 2000-02-18 | 2002-04-26 | Aventis Pharma Sa | Procede de preparation de polyalkylenimines fonctionnalises, compositions les contenant et leurs utilisations |
| FR2813605B1 (fr) * | 2000-09-05 | 2002-10-18 | Aventis Pharma Sa | Composes acidosensibles, leur preparation et utilisations |
| HUP0303379A3 (en) * | 2000-09-05 | 2004-03-01 | Gencell Sa | Acid-sensitive compounds, use thereof and pharmaceutical compositions containing them |
| FR2814370B1 (fr) * | 2000-09-22 | 2004-08-20 | Centre Nat Rech Scient | Utilisation d'un complexe acide nucleique/pei pour le ciblage de cellules souches du cerveau |
| DE10145134A1 (de) * | 2000-10-09 | 2002-05-16 | Bayer Ag | Komplexe zur Einführung von Nukleinsäuren in Zellen |
| US20040048819A1 (en) * | 2000-10-09 | 2004-03-11 | Joachim Simon | Complexes for transferring nucleic acids into cells |
| US20020091242A1 (en) | 2000-10-11 | 2002-07-11 | Michel Bessodes | Acid-sensitive compounds, their preparation and uses |
| CA2437555A1 (en) * | 2001-02-01 | 2002-08-08 | Yiyu Zou | Stabilised polymeric aerosols for pulmonary gene delivery |
| US6652886B2 (en) | 2001-02-16 | 2003-11-25 | Expression Genetics | Biodegradable cationic copolymers of poly (alkylenimine) and poly (ethylene glycol) for the delivery of bioactive agents |
| WO2002100435A1 (en) * | 2001-06-11 | 2002-12-19 | Centre Hospitalier Universitaire De Montreal | Compositions and methods for enhancing nucleic acid transfer into cells |
| WO2003024481A2 (en) | 2001-09-14 | 2003-03-27 | Cytos Biotechnology Ag | Packaging of immunostimulatory substances into virus-like particles: method of preparation and use |
| US20030138407A1 (en) * | 2001-11-02 | 2003-07-24 | Patrick Lu | Therapeutic methods for nucleic acid delivery vehicles |
| EP1479985B1 (en) | 2002-01-17 | 2017-06-14 | Alfa Laval Corporate AB | Submerged evaporator comprising a plate heat exchanger and a cylindric casing where the plate heat exchanger is arranged |
| AU2003231048A1 (en) * | 2002-04-22 | 2003-11-03 | Regents Of The University Of Minnesota | Transposon system and methods of use |
| WO2003099225A2 (en) | 2002-05-24 | 2003-12-04 | Mirus Corporation | Compositions for delivering nucleic acids to cells |
| US7901708B2 (en) | 2002-06-28 | 2011-03-08 | Protiva Biotherapeutics, Inc. | Liposomal apparatus and manufacturing methods |
| US20050196382A1 (en) * | 2002-09-13 | 2005-09-08 | Replicor, Inc. | Antiviral oligonucleotides targeting viral families |
| WO2004024919A1 (en) * | 2002-09-13 | 2004-03-25 | Replicor, Inc. | Non-sequence complementary antiviral oligonucleotides |
| ES2784011T3 (es) | 2002-10-16 | 2020-09-21 | Streck Inc | Procedimiento y dispositivo para recoger y preservar las células para su análisis |
| US7153905B2 (en) * | 2003-03-21 | 2006-12-26 | The General Hospital Corporation | Hyperbranched dendron and methods of synthesis and use thereof |
| EP1648519B1 (en) | 2003-07-16 | 2014-10-08 | Protiva Biotherapeutics Inc. | Lipid encapsulated interfering rna |
| US7803397B2 (en) | 2003-09-15 | 2010-09-28 | Protiva Biotherapeutics, Inc. | Polyethyleneglycol-modified lipid compounds and uses thereof |
| EP1737956A2 (en) * | 2004-03-01 | 2007-01-03 | Massachusetts Institute of Technology | Rnai-based therapeutics for allergic rhinitis and asthma |
| US20050215507A1 (en) * | 2004-03-04 | 2005-09-29 | Massachusetts Institute Of Technology | Therapeutic anti-cancer DNA |
| US20060026699A1 (en) * | 2004-06-04 | 2006-02-02 | Largaespada David A | Methods and compositions for identification of genomic sequences |
| AU2005251403B2 (en) | 2004-06-07 | 2011-09-01 | Arbutus Biopharma Corporation | Cationic lipids and methods of use |
| AU2005252273B2 (en) | 2004-06-07 | 2011-04-28 | Arbutus Biopharma Corporation | Lipid encapsulated interfering RNA |
| CA2572439A1 (en) | 2004-07-02 | 2006-01-12 | Protiva Biotherapeutics, Inc. | Immunostimulatory sirna molecules and uses therefor |
| WO2007051303A1 (en) | 2005-11-02 | 2007-05-10 | Protiva Biotherapeutics, Inc. | MODIFIED siRNA MOLECULES AND USES THEREOF |
| US7915399B2 (en) | 2006-06-09 | 2011-03-29 | Protiva Biotherapeutics, Inc. | Modified siRNA molecules and uses thereof |
| US20080312174A1 (en) * | 2007-06-05 | 2008-12-18 | Nitto Denko Corporation | Water soluble crosslinked polymers |
| EP2207570A2 (en) * | 2007-09-14 | 2010-07-21 | Nitto Denko Corporation | Drug carriers |
| EP2047858A1 (en) | 2007-10-10 | 2009-04-15 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Combination products for treating cancer |
| EP2212425A2 (de) | 2007-11-22 | 2010-08-04 | Biontex Laboratories Gmbh | Verbesserung von transfektionsergebnissen nicht-viraler genliefersysteme durch beeinflussung des angeborenen immunsystems |
| DE102008023913A1 (de) | 2008-05-16 | 2009-11-19 | Biontex Laboratories Gmbh | Verbesserung von Transfektionsergebnissen nicht-viraler Genliefersysteme durch Beeinflussung des angeborenen Immunsystems |
| DE102007056488A1 (de) | 2007-11-22 | 2009-07-23 | Biontex Laboratories Gmbh | Steigerung von Transfektionseffizienzen nicht-viraler Genliefersysteme durch Blockierung des angeborenen Immunsystems |
| DE102008016275A1 (de) | 2008-03-28 | 2009-11-19 | Biontex Laboratories Gmbh | Verbesserung von Transfektionsergebnissen nicht-viraler Genliefersysteme durch Blockierung des angeborenen Immunsystems |
| GB0724253D0 (en) | 2007-12-12 | 2008-01-30 | Fermentas Uab | Transfection reagent |
| AU2008342535B2 (en) | 2007-12-27 | 2015-02-05 | Arbutus Biopharma Corporation | Silencing of polo-like kinase expression using interfering RNA |
| US7687027B2 (en) * | 2008-02-27 | 2010-03-30 | Becton, Dickinson And Company | Cleaning compositions, methods and materials for reducing nucleic acid contamination |
| FR2928373B1 (fr) * | 2008-03-05 | 2010-12-31 | Centre Nat Rech Scient | Polymere derive de la polyethylenimine lineaire pour le transfert de gene. |
| AU2009236219B8 (en) | 2008-04-15 | 2015-06-25 | Arbutus Biopharma Corporation | Silencing of CSN5 gene expression using interfering RNA |
| CN102119217B (zh) | 2008-04-15 | 2015-06-03 | 普洛体维生物治疗公司 | 用于核酸递送的新型制剂 |
| CA2722835C (en) * | 2008-05-15 | 2018-11-27 | National Research Council Of Canada | Process, vectors and engineered cell lines for enhanced large-scale transfection |
| CA2740000C (en) | 2008-10-09 | 2017-12-12 | Tekmira Pharmaceuticals Corporation | Improved amino lipids and methods for the delivery of nucleic acids |
| US20100167271A1 (en) * | 2008-12-30 | 2010-07-01 | Streck, Inc. | Method for screening blood using a preservative that may be in a substantially solid state form |
| US11634747B2 (en) * | 2009-01-21 | 2023-04-25 | Streck Llc | Preservation of fetal nucleic acids in maternal plasma |
| DE102009006606A1 (de) | 2009-01-29 | 2010-08-05 | Philipps-Universität Marburg | Nicht-virales Transfektionsmittel |
| WO2010096323A1 (en) | 2009-02-18 | 2010-08-26 | Streck, Inc. | Preservation of cell-free nucleic acids |
| WO2010125544A1 (en) | 2009-04-30 | 2010-11-04 | Genetic Immunity Kft. | Immunogenic nanomedicine composition and preparation and uses thereof |
| US9018187B2 (en) | 2009-07-01 | 2015-04-28 | Protiva Biotherapeutics, Inc. | Cationic lipids and methods for the delivery of therapeutic agents |
| WO2011000106A1 (en) | 2009-07-01 | 2011-01-06 | Protiva Biotherapeutics, Inc. | Improved cationic lipids and methods for the delivery of therapeutic agents |
| CA2767127A1 (en) | 2009-07-01 | 2011-01-06 | Protiva Biotherapeutics, Inc. | Novel lipid formulations for delivery of therapeutic agents to solid tumors |
| US9856456B2 (en) | 2009-10-12 | 2018-01-02 | Thermo Fisher Scientific Baltics Uab | Delivery agent |
| US20130079382A1 (en) | 2009-10-12 | 2013-03-28 | Larry J. Smith | Methods and Compositions for Modulating Gene Expression Using Oligonucleotide Based Drugs Administered in vivo or in vitro |
| GB0917792D0 (en) | 2009-10-12 | 2009-11-25 | Fermentas Uab | Delivery agent |
| EP3103883A1 (en) | 2009-11-09 | 2016-12-14 | Streck, Inc. | Stabilization of rna in and extracting from intact cells within a blood sample |
| US9247720B2 (en) | 2010-03-24 | 2016-02-02 | Institut National de la Santé et de la Recherche Médicale | Primate model from the family cercopithecidae infected by a HBV strain of human genotype |
| EP2552460A1 (en) | 2010-03-29 | 2013-02-06 | Universite De Strasbourg | Polymers for delivering molecules of interest |
| EP2582387A2 (en) | 2010-06-17 | 2013-04-24 | The United States Of America As Represented By The Secretary, National Institutes Of Health | Compositions and methods for treating inflammatory conditions |
| CA2802463C (en) | 2010-06-22 | 2019-02-26 | Dna Therapeutics | Optimized in vivo delivery system with endosomolytic agents for nucleic acid conjugates |
| US9006417B2 (en) | 2010-06-30 | 2015-04-14 | Protiva Biotherapeutics, Inc. | Non-liposomal systems for nucleic acid delivery |
| US9956281B2 (en) | 2011-05-04 | 2018-05-01 | Streck, Inc. | Inactivated virus compositions and methods of preparing such compositions |
| WO2013040552A2 (en) | 2011-09-16 | 2013-03-21 | Georgia Health Sciences University | Methods of promoting immune tolerance |
| CA2856116A1 (en) | 2011-11-17 | 2013-05-23 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Therapeutic rna switches compositions and methods of use |
| RS57066B1 (sr) | 2011-11-24 | 2018-06-29 | Genethon | Sa industrijskim farmaceutskim primenama kompatibilan skalabilan proizvodni sistem lentiviralnog vektora |
| US9035039B2 (en) | 2011-12-22 | 2015-05-19 | Protiva Biotherapeutics, Inc. | Compositions and methods for silencing SMAD4 |
| BR112014029807A2 (pt) * | 2012-06-08 | 2017-06-27 | Ethris Gmbh | administração pulmonar de rna mensageiro |
| CN103059295B (zh) * | 2012-09-26 | 2016-01-13 | 上海交通大学 | 疏水修饰的聚乙烯亚胺及其作为蛋白质载体的用途 |
| ES2919864T3 (es) | 2012-10-05 | 2022-07-28 | Biontech Delivery Tech Gmbh | Derivados de poliamina hidroxilada como reactivos de transfección |
| CN112370532A (zh) | 2012-10-08 | 2021-02-19 | 生物技术传送科技有限责任公司 | 作为转染试剂的羧化多胺衍生物 |
| DE102012111891A1 (de) * | 2012-12-06 | 2014-06-12 | Eberhard Karls Universität Tübingen Medizinische Fakultät | Verbesserung der Zielfindungskapazität von Stammzellen |
| ES2938048T3 (es) | 2013-07-24 | 2023-04-04 | Streck Llc | Composiciones y procedimientos para estabilizar las células tumorales circulantes |
| US20160296632A1 (en) | 2013-11-13 | 2016-10-13 | Aequus Biopharma, Inc. | Engineered glycoproteins and uses thereof |
| US10415037B2 (en) | 2014-10-02 | 2019-09-17 | Arbutus Biopharma Corporation | Compositions and methods for silencing hepatitis B virus gene expression |
| EP3034539A1 (en) | 2014-12-19 | 2016-06-22 | Ethris GmbH | Compositions for introducing nucleic acid into cells |
| US11168351B2 (en) | 2015-03-05 | 2021-11-09 | Streck, Inc. | Stabilization of nucleic acids in urine |
| KR20180015145A (ko) | 2015-05-05 | 2018-02-12 | 이섬 리서치 디벨러프먼트 컴파니 오브 더 히브루 유니버시티 오브 예루살렘 엘티디. | 핵산-양이온성 중합체 조성물 및 그의 제조 및 사용 방법 |
| US20180245074A1 (en) | 2015-06-04 | 2018-08-30 | Protiva Biotherapeutics, Inc. | Treating hepatitis b virus infection using crispr |
| US20180208932A1 (en) | 2015-07-29 | 2018-07-26 | Arbutus Biopharma Corporation | Compositions and methods for silencing hepatitis b virus gene expression |
| US20170145475A1 (en) | 2015-11-20 | 2017-05-25 | Streck, Inc. | Single spin process for blood plasma separation and plasma composition including preservative |
| US10010627B2 (en) | 2016-06-03 | 2018-07-03 | International Business Machines Corporation | Modified polycationic polymers |
| US11506655B2 (en) | 2016-07-29 | 2022-11-22 | Streck, Inc. | Suspension composition for hematology analysis control |
| JP7078620B2 (ja) | 2016-11-16 | 2022-05-31 | イミュノミック セラピューティックス， インコーポレイテッド | アレルギーの治療のための核酸 |
| WO2018134310A1 (en) | 2017-01-19 | 2018-07-26 | Universiteit Gent | Molecular adjuvants for enhanced cytosolic delivery of active agents |
| WO2018195527A1 (en) | 2017-04-22 | 2018-10-25 | Immunomic Therapeutics, Inc. | Improved lamp constructs |
| KR20240027895A (ko) | 2017-05-02 | 2024-03-04 | 이뮤노믹 쎄라퓨틱스, 인크. | 암 항원을 포함하는 lamp (리소솜 연관 막 단백질) 구축물 |
| JP2021523185A (ja) | 2018-05-15 | 2021-09-02 | イミュノミック セラピューティックス， インコーポレイテッドＩｍｍｕｎｏｍｉｃ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． | アレルゲンを含む改善されたｌａｍｐ構築物 |
| TW202043256A (zh) | 2019-01-10 | 2020-12-01 | 美商健生生物科技公司 | 前列腺新抗原及其用途 |
| AU2020366515A1 (en) | 2019-10-18 | 2022-04-21 | Immunomic Therapeutics, Inc. | Improved lamp constructs comprising cancer antigens |
| WO2021099906A1 (en) | 2019-11-18 | 2021-05-27 | Janssen Biotech, Inc. | Vaccines based on mutant calr and jak2 and their uses |
| US20230024133A1 (en) | 2020-07-06 | 2023-01-26 | Janssen Biotech, Inc. | Prostate Neoantigens And Their Uses |
| US20230035403A1 (en) | 2020-07-06 | 2023-02-02 | Janssen Biotech, Inc. | Method For Determining Responsiveness To Prostate Cancer Treatment |
| US20230029453A1 (en) | 2020-07-06 | 2023-02-02 | Janssen Biotech, Inc. | Prostate Neoantigens And Their Uses |
| CN112237633B (zh) * | 2020-10-22 | 2023-06-27 | 林君玉 | 一种pei/on复合物及其制备方法和用途 |
| CN117098541A (zh) | 2020-11-25 | 2023-11-21 | 阿卡格拉医药公司 | 用于递送核酸的脂质纳米粒及相关使用方法 |
| GB202108176D0 (en) | 2021-06-08 | 2021-07-21 | Touchlight Ip Ltd | Vector |
| AU2022289260A1 (en) | 2021-06-08 | 2023-12-07 | Touchlight IP Limited | Lentiviral vector |
| WO2023201201A1 (en) | 2022-04-10 | 2023-10-19 | Immunomic Therapeutics, Inc. | Bicistronic lamp constructs comprising immune response enhancing genes and methods of use thereof |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5286634A (en) * | 1989-09-28 | 1994-02-15 | Stadler Joan K | Synergistic method for host cell transformation |
| US5264618A (en) * | 1990-04-19 | 1993-11-23 | Vical, Inc. | Cationic lipids for intracellular delivery of biologically active molecules |
| US5283185A (en) * | 1991-08-28 | 1994-02-01 | University Of Tennessee Research Corporation | Method for delivering nucleic acids into cells |
| AU3945493A (en) * | 1992-04-06 | 1993-11-08 | University Of Medicine And Dentistry Of New Jersey | Paired-ion oligonucleotides and methods for preparing same |
| US6172208B1 (en) * | 1992-07-06 | 2001-01-09 | Genzyme Corporation | Oligonucleotides modified with conjugate groups |
| US5334761A (en) * | 1992-08-28 | 1994-08-02 | Life Technologies, Inc. | Cationic lipids |
-
1994
- 1994-07-13 FR FR9408735A patent/FR2722506B1/fr not_active Expired - Lifetime
-
1995
- 1995-07-07 JP JP50474196A patent/JP4275728B2/ja not_active Expired - Lifetime
- 1995-07-07 US US08/765,679 patent/US6013240A/en not_active Expired - Lifetime
- 1995-07-07 KR KR1019970700200A patent/KR100424802B1/ko not_active IP Right Cessation
- 1995-07-07 AU AU29307/95A patent/AU2930795A/en not_active Abandoned
- 1995-07-07 PT PT95925026T patent/PT770140E/pt unknown
- 1995-07-07 WO PCT/FR1995/000914 patent/WO1996002655A1/fr active IP Right Grant
- 1995-07-07 DK DK95925026T patent/DK0770140T3/da active
- 1995-07-07 DE DE69535540T patent/DE69535540T9/de active Active
- 1995-07-07 ES ES95925026T patent/ES2290952T3/es not_active Expired - Lifetime
- 1995-07-07 CA CA2194797A patent/CA2194797C/fr not_active Expired - Lifetime
- 1995-07-07 MX MX9700270A patent/MX9700270A/es unknown
- 1995-07-07 AT AT95925026T patent/ATE367448T1/de active
- 1995-07-07 EP EP95925026A patent/EP0770140B1/fr not_active Expired - Lifetime
- 1995-07-12 IL IL11456695A patent/IL114566A/xx not_active IP Right Cessation
- 1995-07-13 ZA ZA955849A patent/ZA955849B/xx unknown
-
1997
- 1997-01-07 NO NO19970049A patent/NO323110B1/no not_active IP Right Cessation
- 1997-01-10 FI FI970115A patent/FI119738B/fi not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| CA2194797A1 (fr) | 1996-02-01 |
| NO970049L (no) | 1997-01-07 |
| FI970115A0 (fi) | 1997-01-10 |
| WO1996002655A1 (fr) | 1996-02-01 |
| ZA955849B (en) | 1996-02-21 |
| NO970049D0 (no) | 1997-01-07 |
| JP4275728B2 (ja) | 2009-06-10 |
| FI119738B (fi) | 2009-02-27 |
| PT770140E (pt) | 2007-10-19 |
| DE69535540T2 (de) | 2008-06-19 |
| IL114566A0 (en) | 1995-11-27 |
| KR970704889A (ko) | 1997-09-06 |
| DK0770140T3 (da) | 2007-11-19 |
| MX9700270A (es) | 1997-05-31 |
| ES2290952T3 (es) | 2008-02-16 |
| US6013240A (en) | 2000-01-11 |
| EP0770140A1 (fr) | 1997-05-02 |
| FR2722506B1 (fr) | 1996-08-14 |
| FR2722506A1 (fr) | 1996-01-19 |
| CA2194797C (fr) | 2010-03-23 |
| JPH10502918A (ja) | 1998-03-17 |
| AU2930795A (en) | 1996-02-16 |
| ATE367448T1 (de) | 2007-08-15 |
| IL114566A (en) | 2005-08-31 |
| DE69535540T9 (de) | 2012-03-15 |
| EP0770140B1 (fr) | 2007-07-18 |
| FI970115A (fi) | 1997-01-10 |
| KR100424802B1 (ko) | 2004-06-23 |
| DE69535540D1 (de) | 2007-08-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO323110B1 (no) | Preparat innbefattende en nukleinsyre og kationisk polymer samt anvendelse av polymeren. | |
| US6172048B1 (en) | Composition containing nucleic acids, preparation and uses | |
| US8211468B2 (en) | Endosomolytic polymers | |
| US8217015B2 (en) | Endosomolytic polymers | |
| KR19980702200A (ko) | 핵산 함유 조성물과 이의 제조방법 및 용도 | |
| US20010044412A1 (en) | Compositions and methods for drug delivery using amphiphile binding molecules | |
| ES2265569T3 (es) | Composicion farmaceutica que mejora la transferencia de genes in vivo. | |
| US8658150B2 (en) | Polymer derived from linear polyethylenimine for gene transfer | |
| US20020031763A1 (en) | Cationic polymers, complexes associating said cationic polymers with therapeutically active substances comprising at least one negative charge, in particular nucleic acids, and their use in gene therapy | |
| AU720697B2 (en) | Pharmaceutical composition which is useful for the transfection of nucleic acids, and uses thereof | |
| MXPA01012802A (es) | Copolimeros para el transporte de acidos nucleicos a las celulas. | |
| AU737314B2 (en) | Nucleic acid containing composition, preparation and uses of same | |
| RU2537262C2 (ru) | Молекулярные конъюгаты с поликатионным участком и лигандом для доставки в клетку и ядро клетки днк и рнк | |
| EP1210122A1 (en) | Gene expression with covalently modified polynucleotides | |
| MXPA97006016A (en) | Composition containing nucleic acids, preparation and use | |
| Kabiru | DNA condensation and packaging for potential application in gene therapy | |
| Ning | A bioresponsive peptide as a single component gene vector | |
| LEI | Intrathecal delivery of transgene to promote nerve regeneration | |
| MXPA98001920A (en) | Pharmaceutical composition useful for the transfection of nucleic acids and its u |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| CREP | Change of representative |
Representative=s name: EHRNER & DELMAR PATENTBYRA AB, BOX |
|
| CREP | Change of representative |
Representative=s name: ZACCO NORWAY AS, POSTBOKS 2003 VIKA |
|
| MK1K | Patent expired |